TLR3 agonists as immunotherapeutic agents.
Nicodemus
Christopher F
CF
Berek
Jonathan S
JS
D000818:Animals; D016503:Drug Delivery Systems; D015673:Fatigue Syndrome, Chronic / Q000188:drug therapy; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D007249:Inflammation; D007369:Interferon Inducers / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D018345:Mice, Knockout; D011070:Poly I-C / Q000494:pharmacology / Q000627:therapeutic use; D011072:Poly U / Q000627:therapeutic use; D012327:RNA Virus Infections / Q000276:immunology; D012328:RNA Viruses / Q000276:immunology; D012330:RNA, Double-Stranded / Q000276:immunology; D051196:Toll-Like Receptor 3 / Q000819:agonists* / Q000172:deficiency
D007155:Immunologic Factors; D007369:Interferon Inducers; D012330:RNA, Double-Stranded; C495344:TLR3 protein, human; C519703:TLR3 protein, mouse; D051196:Toll-Like Receptor 3; D011072:Poly U; C047490:poly(I).poly(c12,U); D011070:Poly I-C